


Presently Pending Claims


Language to be added has been **bolded and underlined**, while language to be deleted has been ~~**bolded and striken-through**~~.

21. (Currently amended) A compound represented by the structural formula I




or a pharmaceutically acceptable salt or solvate thereof; wherein:

R¹ is



R² is ~~selected from the group consisting of H, alkyl, aryl, arylalkyl, heteroarylalkyl, alkylketone, arylketone, alkyl, haloalkyl, cycloalkyl, cycloheteroalkyl, cycloalkylalkyl, alkylsulfonyl, arylsulfonyl, alkoxyalkyl, or amide;~~

R³ is selected from the group consisting of ~~aryl, 6-membered heteroaryl, fluorenyl;~~ and ~~diphenylmethyl,~~ 6-membered heteroaryl-N-oxide,



, wherein said ~~aryl, fluorenyl, diphenyl~~ or 6-membered heteroaryl **or heteroaryl-N-oxide is pyrimidine or pyrimidine-N-oxide respectively, each of which** is optionally substituted with 1-4 substituents which can be the same or different and are independently selected from the group consisting of R¹¹, R¹², R¹³, R¹⁴ and R¹⁵;

R⁴ is 1-3 substituents selected from the group consisting of H, halo, alkyl, haloalkyl, alkoxy, cycloalkyl, amide, CF₃, OCF₃, aryl, heteroaryl, -XR⁷, -CN, -CO₂H, -

CO_2R^{22} , R^8 -aryl(C_1 - C_6)alkyl-, R^8 -heteroaryl(C_1 - C_6)alkyl-, $-\text{C}(\text{O})\text{NR}^{21}\text{R}^{22}$, $-\text{C}(\text{O})\text{NH}_2$, wherein R^4 can be the same or different and is independently selected when there is more than one R^4 present;

~~R^5 is selected from the group consisting of H, arylalkyl, (C_1 - C_6)alkyl, R^8 -aryl(C_1 - C_6)alkyl, R^8 -heteroaryl(C_1 - C_6)alkyl, SO_2 -(C_1 - C_6)alkyl, SO_2 -(C_3 - C_6)cycloalkyl, SO_2 -aryl, R^8 -aryl- SO_2 -, $\text{C}(\text{O})$ -(C_1 - C_6)alkyl, $\text{C}(\text{O})$ -(C_4 - C_6)cycloalkyl, R^8 -aryl- $\text{C}(\text{O})$ -, $\text{C}(\text{O})\text{NR}^{21}\text{R}^{22}$, and $\text{SO}_2\text{NR}^{21}\text{R}^{22}$;~~

~~R^6 is H, (C_1 - C_6)alkyl, or (C_1 - C_6)haloalkyl;~~

R^7 is selected from the group consisting of aryl, substituted aryl, heteroaryl, alkyl, haloalkyl and cycloalkyl;

R^8 is 1, 2 or 3 substituents selected from the group consisting of H, halo, (C_1 - C_6)alkyl, (C_1 - C_6)alkoxy, $-\text{CF}_3$, $-\text{OCF}_3$, $\text{CH}_3\text{C}(\text{O})$ -, $-\text{CN}$, CH_3SO_2 -,

CF_3SO_2 - and $-\text{NH}_2$, wherein R^8 can be the same or different and is independently selected when there are more than one R^8 present;

R^9 , R^{10} and B can be the same or different and are each independently selected from the group consisting of hydrogen, (C_1 - C_6)alkyl, and $-(\text{C}_1$ - C_6)haloalkyl;

R^{11} and R^{12} can be the same or different and are each independently selected from the group consisting of (C_1 - C_6)alkyl, $-(\text{C}_1$ - C_6)haloalkyl, halogen, $-\text{NR}^{19}\text{R}^{20}$, $-\text{OH}$, CF_3 , $-\text{OCH}_3$, $-\text{O}$ -acyl, and $-\text{OCF}_3$;

R^{13} is selected from the group consisting of hydrogen, R^{11} , H, phenyl, $-\text{NO}_2$, $-\text{CN}$, $-\text{CH}_2\text{F}$, $-\text{CHF}_2$, $-\text{CHO}$, $-\text{CH}=\text{NOR}^{19}\text{R}^{20}$, pyridyl-N-oxide, pyrimidinyl, pyrazinyl, $\text{N}(\text{R}^{20}\text{R}^{20})\text{CONR}^{20}\text{R}^{21}\text{R}^{20}\text{R}^{21}$, $-\text{NHCONH}(\text{chloro}-(\text{C}_1$ - C_6)alkyl), $-\text{NHCONH}((\text{C}_3$ - $\text{C}_{10})$ -cycloalkyl(C_1 - C_6)alkyl), $-\text{NHCO}(\text{C}_1$ - C_6)alkyl, $-\text{NHCOCF}_3$, $-\text{NHCOCF}_3$, $-\text{NHSO}_2\text{N}((\text{C}_1$ - C_6)alkyl) $_2$, $-\text{NHSO}_2(\text{C}_1$ - C_6)alkyl, $-\text{N}(\text{SO}_2\text{CF}_3)_2$, $-\text{NHCO}_2(\text{C}_1$ - C_6)alkyl, (C_3 - C_{10})cycloalkyl, $-\text{SR}^{22}$, $-\text{SOR}^{22}$, $-\text{SO}_2\text{R}^{22}$, $-\text{SO}_2\text{NH}(\text{C}_1$ - C_6 alkyl), $-\text{OSO}_2(\text{C}_1$ - C_6)alkyl, $-\text{OSO}_2\text{CF}_3$, hydroxy(C_1 - C_6)alkyl, $-\text{CONR}^{19}\text{R}^{20}$, $-\text{CON}(\text{CH}_2\text{CH}_2\text{-O-CH}_3)_2$, $-\text{OCONH}(\text{C}_1$ - C_6)alkyl, $-\text{CO}_2\text{R}^{19}\text{R}^{20}$, $-\text{Si}(\text{CH}_3)_3$ and $-\text{B}(\text{OC}(\text{CH}_3)_2)_2$;

R^{14} is selected from the group consisting of (C_1 - C_6)alkyl, $-(\text{C}_1$ - C_6)haloalkyl $-\text{NH}_2$ and R^{15} -phenyl;

R^{15} is 1-3 substituents selected from the group consisting of hydrogen, (C_1 - C_6)alkyl, $-(\text{C}_1$ - C_6)haloalkyl, $-\text{CF}_3$, $-\text{CO}_2\text{R}^{20}$, $-\text{CN}$, (C_1 - C_6)alkoxy and halogen; wherein R^{15} can be the same or different and is independently selected when there are more than one R^{15} present;

~~R¹⁶ and R¹⁷ can each be the same or different and are each independently selected from the group consisting of hydrogen and (C₁-C₆)alkyl, or~~

~~R¹⁶ and R¹⁷ together are a C₂-C₆ alkylene group and with the carbon to which they are attached form a spiro ring of 3 to 6 carbon atoms;~~

R¹⁹, R²⁰ and R²¹ can each be the same or different and are each independently selected from the group consisting of H, (C₁-C₆)alkyl and (C₃-C₆)cycloalkyl;

R²² is selected from the group consisting of (C₁-C₆)alkyl, -(C₁-C₆)haloalkyl, (C₂-C₆)hydroxyalkyl, (C₂-C₆)alkylene, (C₃-C₆)cycloalkyl, aryl and aryl(C₁-C₆)alkyl-;

A is selected from the group consisting of H, (C₁-C₆)alkyl, and (C₂-C₆) alkenyl.













M is aryl ~~or heteroaryl~~ optionally substituted with R⁴;


































Q is CH or N; and


































X is selected from the group consisting of CH₂, SO₂, SO, S, and O, with the following proviso:





































when R¹ is phenyl, ~~pyridyl, thiophenyl~~ or naphthyl, R² cannot be H, -(C₁-C₆)alkyl or -C(O)-(C₁-C₆)alkyl.





































22. (Currently amended) A compound having the structural formula I according to claim 21 or a pharmaceutically acceptable salt or solvate thereof, wherein R⁹, R¹⁰ and B are H, A is -CH₃, and R¹, R² and R³ are as defined in the following table:





































#	R ¹	R ²	R ³
8			
9			
10			
11			































12			
13			
14			
15			
16			
17			
18			
19			
20			
21			
22			





































23			
24			
25			
26			
27			
28			
29			
30			
31			
32			
33			

































34			
35			
36			
37			
38			
39			
40			
41			
42			
43			
44			
46			

50			
51			
52			
53			
58			
59			
60			
61			
62			
63			
65			
66			


































67			
68			
69			
70			
71			
72			
73			
74			
75			
76			
77			
78			





































79			
80			
81			
82			
83			
84			
85			
86			
87			
88			




























89			
90			
91			
92			
93			
94			
95			
96			
97			
98			
99			
100			

101			
102			
103			
104			
105			
106			
107			
108			
109			
110			
111		CH ₃	




23. (Currently amended) A compound according to claim 22 wherein R¹, R² and R³ each represent:

#	R ¹	R ²	R ³
9			
10			
11			
12			
13			
14			
16			
17			
28			
29			
31			


36			
37			
39			
40			
50			
61			
68			
69			
70			
74			
80			
84			




82			
90			
91			
93			
96			
99			
100			
101			
102			

24. (Currently amended) A compound according to claim 23 represented by the structural formulae:



and





or a pharmaceutically acceptable salt or solvate thereof.

25. (Currently amended) A pharmaceutical composition comprising one or more compounds of claim 21 **or a pharmaceutically acceptable salt or solvate thereof.**

26. (Currently amended) A pharmaceutical composition comprising one or more compounds of claim 24 **or a pharmaceutically acceptable salt or solvate thereof.**

27. (Previously presented) The pharmaceutical composition according to claim 25 further comprising one or more pharmaceutically acceptable carriers.

28. (Previously presented) The pharmaceutical composition according to claim 26 further comprising one or more pharmaceutically acceptable carriers.

29. (Currently amended) The pharmaceutical composition according to claim 25, wherein said pharmaceutical composition contains a therapeutically effective amount of said one or more compounds **or a pharmaceutically acceptable salt or solvate thereof.**

30. (Currently amended) The pharmaceutical composition according to claim 26, wherein said pharmaceutical composition contains a therapeutically effective amount of said one or more compounds **or a pharmaceutically acceptable salt or solvate thereof.**

31-40. (Previously canceled)